Cancer Treatment in India: How Good the Option is?

As per the reports by W.H.O, “One out of three women and one out of four men are prone to getting the disease of cancer in the world”. Now these reports are more than sufficient to prove that cancer is one of the deadliest diseases in the world. At present, there are countless people suffering from the disease and are looking for effective medical solutions. Let’s see, how India stands as a destination for these patients.

Now when it comes to cancer treatment in India, our hospitals are well-equipped to fight the disease and save the patients from untimely deaths. Thanks to the ever-improving technologies in the domain of medical science, the cure rate of cancer has reached 70-80%. Backed up by the most advanced technologies and state-of-the-art equipments, many hospitals are offering cost-effective medical solutions for cancer. And costs for cancer treatment are pretty much cheaper in Indian hospitals when compared with the hospitals in the western world.  leading hospital in Delhi,

Any leading hospital in Delhi can offer a comprehensive multidisciplinary, state-of-the-art facility where one can find some of the most competent and highly skilled oncologists providing excellent treatment facilities at affordable costs. Now coming back to cancer treatment in India, there are a number of hospitals offering world class treatment facilities. And therefore, it will not be a problem finding a good one. All you need to do is check the websites of several Cancer Treatments providing hospitals and deciding for one which fits your budget and other requirements.

Therefore, if one is looking at Indian hospitals for receiving very cost-effective medical solutions for cancer, yes, it is a good option. However, if you residing outside India, make sure that you do online research about the leading cancer hospitals in India. You should also take appointments with the surgeons. Also make sure that you carry all the medical reports which could be helpful in your treatments.

About the Author

Medanta-The Medicity is a multi-super specialty hospital, providing quality cancer treatment in India at affordable costs. It is also amongst the best places to visit and seek medical treatments when it comes to heart institute Delhi.

How much is a life worth?

Cost of Cancer Treatment Study’s Design and Methods … $0.00

Silk’n Personal Light-Based Hair Removal Device for Home Use $398.00 The Silk’n is the first home-use hair removal device which gives the user, woman or man, the freedom to receive clinically-proven results in the convenience of their home in a simple, safe, friendly, cost efficient and easy to use device. The patented Home Pulsed Light technology (HPL) of Silk’n is an innovative light energy technology combined with unique acoustic effect, designed exclusively for…

Hydrogen Peroxide: Medical Miracle $17.92 Peroxides are supposed to be bad for you. Free radicals and all that. But now we hear that hydrogen peroxide is good for us. Hydrogen peroxide will put extra oxygen in your blood. There’s no doubt about that. Hydrogen peroxide costs pennies. So if you can get oxygen into the blood cheaply and safely, maybe cancer (which doesn’t like oxygen), emphysema, AIDS, and many other terrible diseases can be…

Overdiagnosed: Making People Sick in the Pursuit of Health $12.45 From a nationally recognized expert, an exposé of the worst excesses of our zeal for medical testing After the criteria used to define osteoporosis were altered, seven million American women were turned into patients—literally overnight. The proliferation of fetal monitoring in the 1970s was associated with a 66 percent increase in the number of women told they needed emergency C-sections, but…

Brain Tumors: Finding the Ark. Meeting the Challenges of Treatment Choices, Side Effects, Childrens Issues, Healthcare Costs and Long Term adjustment $29.95 In this sequel to Brain Tumors: Leaving the Garden of Eden, Dr. Paul continues to guide you through the brain tumor minefield so you have the best chances for quality survival. Here are the key answers to questions about medications, side effects and late effects of treatment, insurance, Medicare & HMOs, clinical trials, heredity, brain tumors in children, Complementary and Alternative Medicines &…

Cancer Treatment Drugs $41.94 Cancer Treatment Drugs

Costs $11.49 Costs

The Cancer Treatment Revolution $6.99 For the millions who face cancer, there is good news: today, many patients with formerly fatal diagnoses will enter complete remission and live their lives in good health. Thousands of people every year are surviving cancers that were considered fatal just a decade or two ago. Great strides are being made in the treatment of cancer using a combination of modern surgical techniques, radiation, chemotherapy treatment, and smart drugs custom-designed to block the growth of cancer cells. In this fascinating and hopeful book, world-renowned doctor and researcher Dr. David G. Nathan reveals both the scientific and human aspects of the war against cancer and explores what it means to have and to fight cancer in the 21st century.

Canine cancer Sweatshirt by CafePress $39.5 The Magic Bullet Fund helps people who have a dog with cancer but cannot afford treatment costs. Proceeds from sales of the all items allow the Magic Bullet Fund to help more dogs fight cancer. Canine cancer Sweatshirt Tee, TShirt, Shirt Warm up in our stylin’ Hanes Heavyweight 90/10 cotton/polyester sweatshirt. Thick but not bulky, for maximum comfort and durability whether you’re working out or hanging out. 10.1 oz. patented PrintPro174; fabric in a 90/10 cotton/polyester

Aging and Chronic Disorders $18.09 Used – Aging and Chronic Disease provides new perspectives on how aging is affected by chronic disease. The book focuses on how chronic disorders, such as diabetes, arthritis, cardiovascular disease, and cancer influence stress, coping, and quality of life among older adults. The book emphasizes how management of risk factors for chronic diseases, new treatment and rehabilitation outcomes, social support, and patient education can reduce health care costs and improve coping strategies, quality o

Aging and Chronic Disorders $18.09 New – Aging and Chronic Disease provides new perspectives on how aging is affected by chronic disease. The book focuses on how chronic disorders, such as diabetes, arthritis, cardiovascular disease, and cancer influence stress, coping, and quality of life among older adults. The book emphasizes how management of risk factors for chronic diseases, new treatment and rehabilitation outcomes, social support, and patient education can reduce health care costs and improve coping strategies, quality of

An iterative phase I/II/I clinical trial design incorporating genomic biomarker information. $49.99 The goal of a phase I cancer clinical trial is to determine the maximum tolerated dose (MTD) or the recommended phase II dose (RP2D) of a new drug that corresponds to some given acceptable rate of dose limiting toxicity. However, a common limitation to the generalizability of phase I and phase II clinical trials is high patient heterogeneity with respect to toxicity and efficacy. A poor estimate of the MTD may put patients at unprecedented risks by assigning subtherapeutic or excessively toxic doses. Ignoring patient heterogeneity with respect to efficacy may cause phase II trials to have extremely large false positive and false negative error rates within subpopulations. In either case, the large scale phase III clinical trial conducted with an inappropriate dose may put patients in the study at high risk, and doom a potential effective and safe treatment after substantial investment in its development.;It is believed that most cancer clinical trials involve a heterogeneous group of patients at the molecular level. This heterogeneity is one of the reasons that not all patients with cancer respond to a given drug. In view of this patient heterogeneity, it is clear that a “one size fits all” approach may not be suitable in the drug development process. Therefore, it is important to be able to predict which patients are most likely to benefit from a new drug. This would not only save patients from unnecessary risk of toxicity but might facilitate their receiving beneficial treatment, and it would shorten the time required for drug development and lower associated costs. The goals of this research are two fold: (1) to investigate statistical issues involved in applying a genomic biomarker classification method to account for patient heterogeneity with respect to toxicity and efficacy response in early phase clinical trials, allowing for the possibility of differing treatment efficacy among subpopulations, and (2) developing a new design approach that incorporates

Analysis of HER2 testing in breast cancer: Disparities, cost-effectiveness, and patterns of care. $69 HER2 breast cancer is an aggressive disease that occurs in 20–30% of the breast cancer population. Treatment for HER2 breast cancer includes use of an anti-HER2 monoclonal antibody, trastuzumab. Testing for HER2 is of critical importance due to the adverse side effects and substantial costs associated with this anti-HER2 treatment. Currently, two kinds of tests, Fluorescence In Situ Hybridization (FISH) and Immunohistochemistry (IHC), are FDA approved for determination of HER2 status in breast cancers.;Clinical and non clinical factors that affect the choice HER2 test and the use of anti-HER2 therapy in breast cancer were analyzed using a data set containing information from six outpatient oncology clinics in the United States. The analysis showed that geographic location, cancer stage, and diagnosis date (pre- or post-publication of testing guidelines) have significant effects on choice of test. With regard to trastuzumab prescription, geographic location and HER2 status have significant effects on the prescription of trastuzumab. In addition, there was a non-significant trend for certain Medicare patients not to receive trastuzumab therapy. These findings indicate that disparities are present in breast cancer care based on geography and cancer stage, and highlight the importance of testing guidelines.;The cost effectiveness of FISH vs. IHC was determined, by considering the financial and health-related costs associated with testing and subsequent treatment as well as the accuracy of each test. The results show that FISH is the optimal choice for HER2 testing and is more cost-effective than IHC.